INTRODUCTION AND OBJECTIVES: Combination therapies for metastatic castration resistant prostate cancer (mCRPC) are currently being investigated. Recently, the phase III ERA-223 trial was unblinded due to an increased incidence of deaths and bone fractures in the radium-223 with abiraterone arm compared to the placebo plus abiraterone arm. Using a large, real-world cohort, we aimed to evaluate the risk of all-cause mortality (ACM) and skeletal related events (SRE) among men who received radium-223 with or without abiraterone/enzalutamide. METHODS: We reviewed charts of all men with mCRPC in the entire Veterans Affairs (VA) system alive as of January 1st, 2013 who received radium-223. Cox models were used to test the association between concomitant radium-223 use with abiraterone/enzalutamide on ACM and SRE vs. radium-223 alone. Four sensitivity analyses were done: (1) men with 30 days of treatment overlap, (2) men with 60 days of overlap, (3) men who received intermittent radium, defined as less than an average of 0.8 infusions/month, and (4) men stratified by use of denosumab/bisphosphonate at radium-223 start.
RESULTS: 116/318 (37%) men were taking abiraterone or enzalutamide at the same time as radium-223. On univariable and multivariable analysis, there was no significant difference in ACM between men who did and did not receive abiraterone/enzalutamide while on radium-223 (p[0.33). Similarly, there was no difference in time to SRE in men on concomitant abiraterone/enzalutamide (p[0.88). There was no difference in ACM for any of the sensitivity analyses, but there was a trend to increased SRE risk in men who had 30 days of therapy overlap (p[0.051) and men who received radium at regular intervals (p[0.064). There was no association with ACM or SRE after stratifying by use of denosumab /bisphosphonates.
CONCLUSIONS: Despite the common use of combination therapy, there was no increased ACM risk. There was a trend to increased SRE risk in some subgroups, but this was not significant. Further work needs to evaluate the optimal sequence and timing of combination therapies with a focus on safety profile.
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Cosimo De Nunzio*, Giorgia Tema, Riccardo Lombardo, Olivia Voglino, Valeria Baldassarri, Fabiana Cancrini, Angela Sica, Luca Sarchi, Antonio Nacchia, Antonio Cicione, Andrea Tubaro, Rome, Italy INTRODUCTION AND OBJECTIVES: Aim of our study was to analyze adverse events (AEs) associated with ENZ and ABI over time and to compare real life data from Eudra-Vigilance to registry studies.
METHODS: Eudra-Vigilance database is the system for managing and analyzing information on suspected adverse reactions to medicines which have been authorized or being studied in clinical trials in the European Economic Area (EEA). AEs were analyzed in two frame times: from 2013 to 2015 and from 2016 to 2018 as well a meta-analysis of registry studies was performed. Pooled Relative Risk (PRR) were used to compare data.
RESULTS: Data from the registry study indicates that patients treated with ENZ had a statistically significant higher risk of asthenia, fatigue, nervous system and vascular disorders when compared to
